Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New knee injection shows promise in early safety trial

NCT ID NCT06263270

First seen Jan 08, 2026 · Last updated May 21, 2026 · Updated 19 times

Summary

This early-stage study tested whether an experimental drug called CYT-108 is safe for people with mild to moderate knee osteoarthritis. Nineteen participants received either the drug or a placebo injection into the knee, and were monitored for 26 weeks. The main goal was to check for side effects, while also measuring pain, stiffness, and daily function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Emeritus Research

    Camberwell, Victoria, 3124, Australia

  • Novatrials

    Kotara, New South Wales, 2289, Australia

  • University of Sunshine Coast Clinical Trials

    Sunshine Coast, Birtinya QLD, 4575, Australia

Conditions

Explore the condition pages connected to this study.